Clinical Scorecard: Evaluation of 18 F-fluciclovine PET Imaging for Monitoring Glioblastoma Tumor Volumes Throughout Surgical and Radiotherapeutic Interventions
At a Glance
Category
Detail
Condition
Glioblastoma, an aggressive primary malignant brain tumor
Key Mechanisms
18 F-Fluciclovine PET imaging targets amino acid transporters ASCT2 and LAT1 to detect hypermetabolic tumor volumes beyond conventional MRI
Target Population
Adults with clinically suspected or biopsy-confirmed isocitrate dehydrogenase-wildtype glioblastoma undergoing maximal safe tumor resection and adjuvant chemoradiation
Care Setting
Comprehensive cancer center with multidisciplinary neuro-oncology, neurosurgery, radiation oncology, and neuroradiology teams
Key Highlights
18 F-Fluciclovine PET detects larger hypermetabolic tumor volumes than contrast-enhancing MRI, correlating better with true tumor extent
The radiotracer has lower background uptake in normal grey matter and dual amino acid transporter targeting, enhancing glioma detection accuracy
Serial imaging at multiple treatment timepoints shows 18 F-Fluciclovine volumes decrease post-surgery and radiation but do not completely resolve, reflecting tumor biology
Guideline-Based Recommendations
Diagnosis
Use 18 F-Fluciclovine PET as a complementary imaging modality to conventional MRI for more accurate delineation of glioblastoma tumor extent
Consider 18 F-Fluciclovine PET imaging preoperatively and during post-treatment monitoring to assess residual and infiltrative tumor
Management
Incorporate 18 F-Fluciclovine PET findings to guide maximal safe tumor resection and targeted radiotherapy planning
Use PET imaging to identify hypermetabolic non-contrast-enhancing tumor regions that may benefit from treatment
Monitoring & Follow-up
Perform serial 18 F-Fluciclovine PET scans at defined treatment intervals: preoperative, pre-radiation, early post-radiation, and 6 months post-radiation
Compare PET volumes with MRI T1 contrast-enhanced and FLAIR sequences to evaluate treatment response and tumor progression
Risks
Exclude patients with gadolinium or 18 F-Fluciclovine allergies, renal failure (eGFR <60 mL/min/1.73m2), pregnancy, or MRI contraindications
Be aware of limited availability of 18 F-Fluciclovine radiopharmaceuticals and potential study recruitment challenges
Patient & Prescribing Data
Adults with IDH-wildtype glioblastoma eligible for standard-of-care surgery and chemoradiation
18 F-Fluciclovine PET imaging can identify tumor volumes beyond MRI contrast enhancement, potentially improving surgical and radiotherapy targeting and monitoring
Clinical Best Practices
Obtain informed consent and ensure patient eligibility criteria including MRI safety and renal function prior to 18 F-Fluciclovine PET imaging
Use multidisciplinary team evaluation for treatment planning integrating PET and MRI findings
Schedule serial imaging at standardized timepoints to monitor tumor volume changes throughout treatment
Interpret PET hypermetabolic volumes in conjunction with MRI T1C and FLAIR sequences to guide clinical decisions
Recognize that 18 F-Fluciclovine PET volumes typically exceed T1C volumes but are smaller than FLAIR volumes, reflecting infiltrative tumor biology
by Samir A. Dagher, Jason M. Johnson, Rania M.M. Mohamed, Shehbaz Ansari, Osama Mawlawi, Ho-Ling Liu, Max Wintermark, Dawid Schellingerhout, Lesley Flynt, Debra N. Yeboa, Jeffrey S. Weinberg, Sherise D. Ferguson, Maria K. Gule-Monroe
